Jing Xie1, Yufeng Wu2, Xiaojie Bian1, Dongqin Chen1, Qi Gui1, Jianan Huang3. 1. Department of Oncology, The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, P. R. China. 2. Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital Zhengzhou, Henan, P. R. China. 3. Department of Respiratory Medicine, The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, P. R. China.
Abstract
BACKGROUND: Dysregulated long non-coding RNAs (lncRNAs) play critical roles in tumorigenesis and tumor progression. The purpose of this study was to investigate the relationship between lncRNA ZEB1-AS1 expression and non-small cell lung cancer (NSCLC) clinicopathological characteristics and prognosis. METHODS: Expression levels of lncRNA ZEB1-AS1 in 183 NSCLC specimens were determined by quantitative real-time PCR (qRT-PCR). To clarify the clinical significance of lncRNA ZEB1-AS1 in NSCLC, we further explored the relationship between lncRNA ZEB1-AS1 expression and overall survival (OS). RESULTS: In the present study, we found that lncRNA ZEB1-AS1 was upregulated in NSCLC tissues compared to adjacent non-tumor tissues. In addition, upregulated lncRNA ZEB1-AS1 expression was significantly associated with lymph node metastasis and TNM stage (P<0.05). Furthermore, patients with increased expression of lncRNA ZEB1-AS1 had poor OS (HR=3.202, 95% CI=2.018-5.078, P<0.001). Multivariate Cox proportional hazards model analysis demonstrated that high lncRNA ZEB1-AS1 expression was an independent poor prognostic factor for NSCLC patients. CONCLUSION: Our study suggests that increased expression of lncRNA ZEB1-AS1 is related to adverse prognosis of NSCLC and may be a new prognostic biomarker and potential therapeutic target for NSCLC intervention. IJCEP
BACKGROUND: Dysregulated long non-coding RNAs (lncRNAs) play critical roles in tumorigenesis and tumor progression. The purpose of this study was to investigate the relationship between lncRNA ZEB1-AS1 expression and non-small cell lung cancer (NSCLC) clinicopathological characteristics and prognosis. METHODS: Expression levels of lncRNA ZEB1-AS1 in 183 NSCLC specimens were determined by quantitative real-time PCR (qRT-PCR). To clarify the clinical significance of lncRNA ZEB1-AS1 in NSCLC, we further explored the relationship between lncRNA ZEB1-AS1 expression and overall survival (OS). RESULTS: In the present study, we found that lncRNA ZEB1-AS1 was upregulated in NSCLC tissues compared to adjacent non-tumor tissues. In addition, upregulated lncRNA ZEB1-AS1 expression was significantly associated with lymph node metastasis and TNM stage (P<0.05). Furthermore, patients with increased expression of lncRNA ZEB1-AS1 had poor OS (HR=3.202, 95% CI=2.018-5.078, P<0.001). Multivariate Cox proportional hazards model analysis demonstrated that high lncRNA ZEB1-AS1 expression was an independent poor prognostic factor for NSCLCpatients. CONCLUSION: Our study suggests that increased expression of lncRNA ZEB1-AS1 is related to adverse prognosis of NSCLC and may be a new prognostic biomarker and potential therapeutic target for NSCLC intervention. IJCEP
Authors: Zhen Xing; Aifu Lin; Chunlai Li; Ke Liang; Shouyu Wang; Yang Liu; Peter K Park; Li Qin; Yongkun Wei; David H Hawke; Mien-Chie Hung; Chunru Lin; Liuqing Yang Journal: Cell Date: 2014-11-13 Impact factor: 41.582
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: T Li; J Xie; C Shen; D Cheng; Y Shi; Z Wu; X Deng; H Chen; B Shen; C Peng; H Li; Q Zhan; Z Zhu Journal: Oncogene Date: 2015-06-15 Impact factor: 8.756